FIBMED

FibMed is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of innovative therapies for fibrotic diseases. The company focuses on high-unmet-need indications such as non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD). Its lead program, FM-101, is a small molecule inhibitor currently undergoing clinical evaluation in Phase 1 trials for NASH and IPF. FibMed leverages a proprietary drug discovery platform to identify novel targets within the fibrotic signaling pathways, particularly those involving integrins and TGF-beta activation. The company's pipeline includes several early-stage programs aimed at treating various forms of organ fibrosis. FibMed aims to provide transformative treatments that can arrest or reverse the progression of organ fibrosis and improve patient outcomes globally.